


 Cite this: *RSC Adv.*, 2017, 7, 26243

# Functional responsive superparamagnetic core/shell nanoparticles and their drug release properties†

 Zied Ferjaoui,<sup>ID ab</sup> Raphaël Schneider,<sup>ID c</sup> Abdelaziz Meftah,<sup>b</sup> Eric Gaffet<sup>a</sup> and Halima Alem<sup>ID \*a</sup>

The preparation of responsive superparamagnetic iron oxide (SPIO) nanoparticles (NPs), able to carry the anticancer drug doxorubicin (DOX) and to release it in physiological media at the physiological temperature, is one of the major challenges in nanomedicine. In this work, two families of NPs were synthesized. The first one consists of superparamagnetic Fe<sub>3</sub>O<sub>4</sub> NPs functionalized *via* covalent grafting by a biocompatible responsive copolymer based on 2-(2-methoxy)ethyl methacrylate (MEO<sub>2</sub>MA) and oligo(ethylene glycol) methacrylate (OEGMA). The second one consists of the same core/shell NPs but folic acid, a biological cancer targeting molecule, was grafted at the polymer chain end. The core/shell NPs were fully characterized by the combination of spectroscopic and microscopic techniques. The influence of the polymer chain structure in water and in physiological media was studied. We demonstrate that the magnetic properties of the NPs were only influenced by the amount of the grafted polymer and no influence of NP aggregation was evidenced. Indeed, the derived nanostructured materials displayed a combination of the physical properties of the core and the macromolecular behavior of the shell. The drug release experiments confirmed that DOX was largely released above the co-polymer LCST due to the presence of DOX. The nanomaterials developed in this work have high potential as multi-modal cancer therapy tools.

 Received 27th February 2017  
Accepted 10th May 2017

DOI: 10.1039/c7ra02437a

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

One of the major challenges in nanomedicine is to develop materials able to serve as efficient diagnostic and/or therapeutic tools against severe diseases, such as infectious or neurodegenerative disorders.<sup>1</sup> The most powerful diagnosis tool in medical science is MRI (magnetic resonance imaging).<sup>2</sup> To enhance MRI images interpretation, contrast agents were developed to increase the signal/noise ratio. Among them, superparamagnetic iron oxide (SPIO) nanoparticles (NPs) have received a great attention since their development as a liver contrast agent twenty years ago.<sup>3,4</sup> Their properties, originating from their nanosized dimensions, allow different bio-distributions and opportunities compared to the conventional molecular imaging agents.<sup>3,5–8</sup> SPIONPs are already approved by the US Food and Drug Administration (FDA) and have been

greatly investigated due to their good biocompatibility, low toxicity and ease of synthesis.<sup>3,9</sup> Below 27 nm, SPIONPs are superparamagnetic which make them better candidates as diagnostic and/or therapeutic tools compared to the ferri or ferromagnetic NPs.<sup>7</sup> Indeed, SPIONPs do not retain their magnetization once the magnetic field is removed. The opportunity to coat those NPs with a polymer shell that can ensure a better stability of the materials in the body, enhance their biodistribution and give them new functionalities appears as very challenging for medicinal applications. Synthetic processes leading to SPIONPs displaying diameters smaller than 20 nm have emerged in the last decade.<sup>7</sup> Owing to their physical properties, SPIONPs received a great attention in many biomedical applications such as drug delivery platforms,<sup>3,4,7,8</sup> contrast agents,<sup>3</sup> and detoxifying agents for biological fluids.<sup>5,10</sup> Monitoring and controlling the drug loading and its release can be ensured by the development of core/shell NPs. The shell can either improve the drug/cancer cells interactions that can in turn reduce the amount of drugs that have to be administrated during the treatment.

Smart polymers are a subclass of polymers capable to respond to environmental changes such as temperature, pH, ionic strength, electric field, or light, and are a very attractive coating for biomedical applications especially for the controlled release of drugs.<sup>11–13</sup> Thermo-responsive polymers are known to

<sup>a</sup>Institut Jean Lamour (IJL), Université de Lorraine, Department N2EV, UMR CNRS 7198, Parc de Saurupt CS50840, 54011 Nancy, France. E-mail: [halima.alem@univ-lorraine.fr](mailto:halima.alem@univ-lorraine.fr)

<sup>b</sup>Unité Nanomatériaux et Photonique, Faculty of Sciences of Tunis, Tunis El-Manar University, 2092 Tunis, Tunisia

<sup>c</sup>Laboratoire Réactions et Génie des Procédés (LRGP), Université de Lorraine, UMR CNRS 7274, 1 rue Grandville, 54001 Nancy, France

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra02437a



exhibit either an Upper Critical Solution Temperature (UCST) or a Lower Critical Solution Temperature (LCST).<sup>14</sup> When the UCST is reached upon heating, the polymers become hydrophilic while the LCST is the temperature at which the polymer chains shrink leading to their volume decrease due to the release of the water molecule from its backbone and finally to their hydrophobicity. As a consequence, the use of thermoresponsive polymers displaying a LCST in a temperature range of 40–42 °C is of high interest for a further use in core/shell NPs design. At physiological temperature, once the responsive macromolecules grafted at the surface of SPIONPs, they could trap a cancer drug by supramolecular interactions while their hydrophilicity could allow their good dispersion and circulation in the blood. Upon heating locally at 40–42 °C, the drug release could be triggered in a temporal controlled way.<sup>14</sup> Nowadays, many temperature responsive polymers were reported in the literature, but copolymers containing poly(ethylene glycol) moieties have been found to appear as ideal candidates as they are biocompatible and proteins repellent.<sup>15</sup> Copolymers based on the 2-(2-methoxy)ethyl methacrylate (MOE<sub>2</sub>MA) and oligo(ethylene glycol) methacrylate (OEGMA) can exhibit variable LCST depending on the amount of each monomer. As a consequence, the target temperature range mentioned above (40–42 °C) can be reached by choosing the proper MOE<sub>2</sub>MA/OEGMA molar ratio.<sup>16,17</sup> To prepare stable core/shell NPs, the covalent grafting of the copolymer is preferred to a weak electrostatic association that can be debilitated in physiological media. Responsive polymers or copolymers are generally grafted at the surface of SPIONPs by the “grafting-to” process, *i.e.* the copolymer is first synthesized and then grafted at the surface of the NPs. Hence this process could easily lead to very stable and functional nanomaterials, but as a drug will be trapped within the polymer chain, its quantity is directly related to the amount of polymer chains grafted at the surface, and thus to the grafting density.<sup>18,19</sup> To increase the grafting density of the copolymer chains, the grafting-from process is a more suitable process as it allows the growth of the copolymer from the NPs surface.<sup>20</sup> To initiate the polymerization from the surface, controlled polymerization processes (CRP) have become powerful methods to prepare core/shell NPs with well-defined structure.<sup>5,18,19</sup> The

recently developed Activator ReGenerated by Electron Transfer-Atom Transfer Radical Polymerization (ARGET-ATRP) is one of the most promising CRP as it can ensure the growth of the copolymer from NPs surface with less sensitivity to oxygen and requires only a ppm amount of the copper catalyst compared to the ATRP process.<sup>21–23</sup>

In this work, thermoresponsive core/shell NPs for drug delivery purposes were first prepared by growing a responsive statistical copolymer by surface initiated ARGET-ATRP from SPIONPs. Two family of NPs were synthesized. The first one consists in Fe<sub>3</sub>O<sub>4</sub> NPs functionalized by a biocompatible responsive copolymer based on MEO<sub>2</sub>MA and OEGMA, the copolymers were marked as P(MEO<sub>2</sub>MA<sub>*x*</sub>-*co*-OEGMA<sub>100–*x*</sub>), where *x* and (100 – *x*) represent the molar fractions of MEO<sub>2</sub>MA and OEGMA, respectively. In a second step, to enhance the selective binding and the delivery of the drug to the targeted cells *via* the receptor mediated endocytosis, the introduction of specific antibodies or ligands appeared as essential. Among the various ligands available, folic acid (FA) is one of the best candidate owing to its stability, low cost, absence of immunogenicity and especially due its high affinity for folates receptors that are over expressed in various human carcinomas like breast, kidney, lung or ovary.<sup>24,25</sup>

To avoid the FA screening by the polymer chains, grafting FA at the chain end appeared as a good strategy.<sup>26</sup> In the given work, to increase the FA accessibility with the cancer cell wall, a process has been developed that consists in first the growing of a responsive copolymer based on MEO<sub>2</sub>MA, OEGMA and the FA was subsequently grafted at the chain end (Fig. 1). The efficiency of the FA grafting and the final nanomaterials structure were characterized by the combination of spectroscopic and microscopic methods. The drug release capacities of the NPs were investigated by using the Doxorubicin drug.

## 2. Materials and methods

### 2.1 Chemicals

All reagents were purchased from Sigma-Aldrich, excepted ((chloromethyl)phenylethyl)trimethoxysilane (CMPETMS) (Gel-est, >95%). All the reagents were used as received.




Fig. 1 Schematic representation of the surface-initiated ARGET-ATRP polymerization of P(MOE<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>100–*x*</sub>) from Fe<sub>3</sub>O<sub>4</sub>@silane.



## 2.2 Synthesis of Fe<sub>3</sub>O<sub>4</sub> NPs

Superparamagnetic Fe<sub>3</sub>O<sub>4</sub> nanocrystals were synthesized by coprecipitation. A mixture of FeCl<sub>3</sub>·6H<sub>2</sub>O (6 mmol; 1.622 g) and FeSO<sub>4</sub>·7H<sub>2</sub>O (5 mmol; 1.39 g) was dissolved in 40 mL water in a three necked round bottom flask. 5 mL of a 28% (v/v) aqueous ammonia solution were subsequently added to the mixture and the final solution was heated at 90 °C under argon atmosphere with stirring. Then, 4.4 g (14.9 mmol) of sodium citrate in 15 mL water were added dropwise until getting a black solution. The reaction mixture was further stirred for 30 min. Fe<sub>3</sub>O<sub>4</sub> SPIONPs were finally recovered by magnetic separation, washed several times with ethanol and redispersed in 100 mL water.

## 2.3 Synthesis of CMPETMS-coated Fe<sub>3</sub>O<sub>4</sub> NPs (Fe<sub>3</sub>O<sub>4</sub>@silane)

SPIONs were dispersed in 10 mL of toluene under argon. CMPETMS (0.2 mmol, *V* = 49.1 μL) was injected and the mixture stirred for 2 min. Then, 1 mL of an ethanolic solution of tetramethylammonium hydroxide pentahydrate (TMAH) (36.25 mg) was added and the mixture further stirred under argon for 15 min at 50 °C. The mixture was then cooled and SPIONs were separated by centrifugation and washed two times with toluene. The silanized SPIONs were dispersed in 10 mL of toluene and 2 mL of an ethanolic solution of TMAH (36.25 mg) were injected. The reaction was conducted under argon for 30 min at 50 °C under magnetic stirring. The mixture was cooled in a water bath and SPIONPs were separated by centrifugation and washed two times with toluene.

## 2.4 Synthesis of Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>) and Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-*co*-OEGMA<sub>*y*</sub>)-FA NPs

The surface initiated polymerization of P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>) from iron oxide NPs surface was conducted using an adapted protocol described by Alem *et al.*<sup>23</sup> Briefly, in a 100 mL Schlenk flask, 50 mg Fe<sub>3</sub>O<sub>4</sub>@silane NPs were dispersed in 20 mL of a DMF/DMSO mixture (10/90, v/v). 1.6 mL of MEO<sub>2</sub>MA and 1.14 mL of OEGMA were added for the synthesis of Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>60</sub>-OEGMA<sub>40</sub>). 1.26 mL of MEO<sub>2</sub>MA, 1 mL of OEGMA for Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>65</sub>-OEGMA<sub>35</sub>). Once the NPs were completely dispersed, 200 μL of a CuBr<sub>2</sub>/TPMA (0.884 μmol CuBr<sub>2</sub>, 4.3 μmol TPMA) stock solution in DMSO were added to the mixture. The reaction mixture was stirred and heated to 65 °C. Next, 250 μL of a stock solution of hydrazine in DMSO (7.1 mg mL<sup>-1</sup>) were added and the mixture was stirred for 2 h at 65 °C with argon. At the end of the polymerization, the mixture was poured drop by drop into hot Milli-Q water to precipitate the insoluble components. The materials were purified by redispersion of the core/shell NPs in cold water followed by centrifugation of the solution after heating.

Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>) NPs functionalized by FA (Fe<sub>3</sub>-O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>)-FA) were prepared according to a one-pot synthesis protocol similar to that described with Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>). Briefly, 8.33 mg of Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>) NPs and 400 mg of modified FA (see the synthesis protocol in the ESI†) were dispersed in 20 mL ethanol and 200 μL

of the CuBr<sub>2</sub>/TPMA (0.884 μmol CuBr<sub>2</sub>, 4.3 μmol TPMA). The mixture was stirred under argon for 30 min. Next, 250 μL of hydrazine (7.1 mg mL<sup>-1</sup> in DMSO) were added and the mixture stirred under argon for 24 h. At the end of the polymerization, the mixture was poured into hot Milli-Q water to precipitate the insoluble components. The materials were purified by washing with hot Milli-Q water followed by centrifugation.

## 2.5 Association with DOX

Conjugation of DOX with the copolymer was achieved through formation of imine bond, also called Schiff base bond, between the primary amine group of DOX and the aldehyde group of the P(MEO<sub>2</sub>MA<sub>*x*</sub>-*co*-OEGMA<sub>*y*</sub>) polymer. Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>)-FA NPs (2.5 mg) were suspended in 5 mL PBS (pH 7.4). Next, 5 mg of DOX were added (the DOX concentration was 1 mg mL<sup>-1</sup>). The mixture was stirred in the dark for 12 h. Subsequently, the DOX-loaded Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>)-FA NPs were washed with PBS by magnetic decantation ten times until the supernatant solution was clear and that no signal of the DOX could be detected by UV-visible spectroscopy. Then, the DOX-loaded Fe<sub>3</sub>O<sub>4</sub>@P(MEO<sub>2</sub>MA<sub>*x*</sub>-OEGMA<sub>*y*</sub>)-FA NPs were dispersed in 5 mL of PBS. The concentration of released DOX vs. temperature (between 25 and 50 °C) is calculated by measuring the absorbance of the supernatant at 480 nm of the free DOX remaining in solution.

## 2.6 Characterization methods

Dynamic light scattering (DLS) was performed at room temperature using a Malvern zetasizer HsA instrument with an He-Ne laser (4 × 10<sup>-3</sup> W) at a wavelength of 633 nm. The NPs aqueous solutions were filtered through Millipore membranes (0.2 μm pore size). The data were analysed by the CONTIN method to obtain the hydrodynamic diameter and size distribution in each aqueous dispersion of NPs. Transmission electron microscopy characterization: for each sample, one drop of a dispersed solution (for each step of the synthesis) was deposited on holey carbon grids and imaged by transmission electron microscopy (TEM). The Microscope used is an ARM 200F. The crystallographic structure of VN thin films was identified by X-Ray Diffraction (XRD) using Philips PW3710 diffractometer with Cu Kα radiation. Fourier transform infrared (FT-IR) measurements were conducted by using a Nicolet 6700 FT-IR spectrometer equipped with a deuterated triglycine sulphate (DTGS) detector in the 400–7000 cm<sup>-1</sup> wavelength range (*i.e.*, 1.24–25 μm) in a reflexion mode. A SETSYS Supersonic thermobalance (SETARAM) was used for the thermogravimetric measurements. The furnace is made up of a graphite element operating from room temperature up to 1600 °C. The apparatus is controlled by software appointed Calisto. Dry samples of 30 mg were put in an alumina crucible with a volume of 30 μL. The samples were heated from room temperature to 600 °C at a heating rate of 5 °C min<sup>-1</sup> under argon atmosphere. The magnetic properties of the core/shell NPs were studied by superconducting quantum interference device SQUID-VSM combined to Vibrating Sample Magnetometer (Fig. 5 and 6).





### 3. Results and discussion

#### 3.1 Physicochemical properties of the superparamagnetic NPs

**3.1.1 Chemical characterization of SPIONS.** The covalent attachment of the copolymer and FA at the surface of  $\text{Fe}_3\text{O}_4$  NPs was monitored by ATR-FTIR (Fig. 2). The peak relative to the vibration mode of the  $\text{Fe}_3\text{O}_4$  ( $575\text{--}585\text{ cm}^{-1}$ ) can be observed in both spectra. After the growth of  $\text{P}(\text{MEO}_2\text{MA}_x\text{-OEGMA}_y)$  from the NPs surface, new absorption bands located at  $1720$  and  $1110\text{ cm}^{-1}$  are observed and can be assigned to the ester  $\text{C}=\text{O}$  and  $\text{C}-\text{O}$  bonds stretching, respectively. The anchorage of FA was confirmed by the presence of a typical large  $\text{NH}$  stretching peak at  $3400\text{ cm}^{-1}$  originating from the  $\text{N}-\text{H}$  bond involved in hydrogen bond. The typical aromatic  $\text{C}=\text{C}$  stretchings between  $1600$  and  $1450\text{ cm}^{-1}$  can also be seen in the spectrum of  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_x\text{-OEGMA}_y)\text{-FA}$  NPs. The sharp aromatic  $\text{C}-\text{N}$  peak at  $1350\text{ cm}^{-1}$  and the  $\text{N}-\text{H}$  out of plane vibration at  $700\text{ cm}^{-1}$  further confirmed the anchorage of FA at the periphery of  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_x\text{-OEGMA}_y)$  NPs.




Fig. 2 FT-IR spectra of (a)  $\text{Fe}_3\text{O}_4@MEO_2MA\text{-}co\text{-}OEGMA$  (b)  $\text{Fe}_3\text{O}_4@MEO_2MA\text{-}co\text{-}OEGMA\text{-}FA$  NPs.

**3.1.2 Physical characterization of the SPIONPs.** Fig. 3 and S12† show HR-TEM micrographs and XRD patterns of the synthesized SPIONPs, respectively. The NPs displayed spherical shape with an average diameter of  $10 \pm 1.3\text{ nm}$ . The magnetite structure of the SPIONPs (before and after silanization and polymerization) was confirmed by XRD. The XRD patterns exhibit a set of diffraction peaks that can be assigned to the (200), (311), (400), (422), (511) and (440) planes of magnetite (JCPDS no. 00-019-0629) and indicate that the crystalline structure of the NPs was not altered by the silanization.

**3.1.3 Colloidal behavior of the NPs in physiological media.** The average diameter of the core/shell NPs measured by DLS is about  $30\text{--}40\text{ nm}$  (higher hydrodynamic diameters were observed when the amount of OEGMA is increased) (Fig. 4). It is worth to mention that NPs with sizes varying between  $10$  and  $200\text{ nm}$  preferentially accumulate preferentially into tumor than healthy tissue due to the enhanced permeability and retention effect (EPR).<sup>27,28</sup> Indeed, due to the porous vascular architecture of the tumors and the degradation of the lymphatic clearance, the NPs diffusion in tumor tissue is largely enhanced. The  $30\text{--}40\text{ nm}$  hydrodynamic diameter of the NPs developed in this work is then optimal for the EPR effect.

The responsive behavior and the starting temperature at which the NPs started to aggregate was also monitored by DLS. As depicted in Fig. 4, when a solution of  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2MA_{80}\text{-}co\text{-}OEGMA_{20})\text{-FA}$  NPs is heated from  $25$  to  $50^\circ\text{C}$ , their hydrodynamic diameter started to increase at  $30^\circ\text{C}$ , which corresponds to the LCST of  $\text{P}(\text{MEO}_2MA_{60}\text{-}OEGMA_{40})\text{-FA}$  in PBS. For  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2MA_{60}\text{-}OEGMA_{40})\text{-FA}$  and for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2MA_{65}\text{-}OEGMA_{35})\text{-FA}$  NPs, the measured hydrodynamic diameter of the NPs started to increase at  $38$  and  $44^\circ\text{C}$ , respectively. The shift of the LCST towards higher temperatures when increasing the amount of OEGMA, from  $30^\circ\text{C}$  for the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2MA_{80}\text{-}OEGMA_{20})\text{-FA}$  NPs to  $44^\circ\text{C}$  for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2MA_{65}\text{-}OEGMA_{35})\text{-FA}$  NPs, indicates that the thermal properties of the core/shell NPs are completely driven by the macromolecular properties of the copolymer chains (the same evolution of LCST was observed for the samples without FA as shown in Fig. S3†). Finally, to prove that the processes are fully reversible, five successive cycles of heating ( $T > \text{LCST}$ ) and cooling ( $T < \text{LCST}$ ) were conducted. All the




Fig. 3 TEM micrographs of (a)  $\text{Fe}_3\text{O}_4@silane$  NPs, (b)  $\text{Fe}_3\text{O}_4@MEO_2MA\text{-}co\text{-}OEGMA$  and (c)  $\text{Fe}_3\text{O}_4@MEO_2MA\text{-}co\text{-}OEGMA\text{-}FA$  NPs.






Fig. 4 (A) Evolution of  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{80}\text{-co-OEGMA}_{20})\text{-FA}$  (black),  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{65}\text{-co-OEGMA}_{35})\text{-FA}$  (red) and  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})\text{-FA}$  (blue) diameter and aggregation with temperature. The solutions of the NPs dispersed in water below the and above the LCST are illustrated in (A) and (B) respectively.

results are presented in Fig. S4.† A reversible behavior in physiological media upon heating and cooling was demonstrated for all the samples. This behavior is in perfect agreement with the high hydration capacity of the ethylene glycol groups below the collapse temperature and the chains shrinking above the latter. No influence of FA was detected on the collapse temperature of the polymer chains.

**3.1.4 Influence of the amount of copolymer grafted at the surface of SPIONPs.** The organic content of the SPIONPs was determined by TGA measurements in the 25 to 500 °C temperature range (Fig. S5†). The weight loss observed between 25 and 250 °C can be attributed to the evaporation of water molecules. The second weight loss between 250 and 450 °C corresponds to the thermal decomposition of the copolymer. The weight loss varies from 48% for the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{80}\text{-co-OEGMA}_{20})\text{-FA}$  NPs to 43% for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})\text{-FA}$  NPs. This indicates that a high amount of copolymer is grafted at the surface of the NPs. By comparison of our results to previous reports in which the copolymers are grafted at NPs surface by the grafting-to process (amount of copolymer varying from 8 to 15%),<sup>30</sup> it could be noticed that the use of the grafting-from process allows the anchorage of higher amount of polymer at the surface of the SPIONPs. This high density of polymer chains is very promising as the amount of drug that will be encapsulated within the NPs is dependent on the amount of polymer chains grafted on the NPs.

**3.1.5 Magnetic measurements.** The saturated magnetization of the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})\text{-FA}$  and  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{80}\text{-co-OEGMA}_{20})\text{-FA}$  NPs are of  $0.0551 \pm 0.000X \text{ emu g}^{-1}$  and  $0.1976 \pm 0.000X \text{ emu g}^{-1}$ , values lower than that of the uncoated  $\text{Fe}_3\text{O}_4$  NPs ( $0.0017$ ) (Fig. 5). This can be attributed to a decrease in the magnetic interaction with diamagnetic coating.<sup>17</sup> Although the magnetism has decreased, NPs quickly and firmly interact with the magnet (Fig. 5). The remanence ( $M_r$ ) and coercivity ( $H_c$ ) for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_x\text{-co-OEGMA}_y)\text{-FA}$  NPs were close

to zero, which is typical for superparamagnetic NPs.<sup>6-8,10,29</sup> A similar behavior was observed for the samples that do not contain FA (Fig. S6†). To confirm the superparamagnetic behavior of the NPs, Field-Cooling (FC) and the Zero-Field-Cooling (ZFC) experiments were performed. The magnetization-dependent temperature was studied at an applied field of 750 Oe between 5 and 300 K. Fig. 6 shows the ZFC and FC curves of the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})$  sample. The ZFC curves of the NPs are characterized by a gradual increase of the magnetization with the temperature until the blocking temperature ( $T_B$ ), which is related to the progressive rotation of the magnetization of the blocked magnetic NPs toward the field direction.<sup>30</sup> Above the  $T_B$ , the magnetization started to decrease with the temperature which indicates that the NPs magnetization is free to align with the magnetic field during the measurement. This special behaviour is the fingerprint of superparamagnetism. As can be seen in Fig. 6, the ZFC curve indicates a blocking temperature of about 250 K, and above this temperature the core/shell NPs are superparamagnetic, in other word the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})$  display superparamagnetic behavior at room temperature and above.

**3.1.6 DOX release properties of the SPIONPs.** DOX was chosen as model drug to determine the drug-release properties of the NPs. DOX is one of the most used chemotherapeutic anti-cancer drug and its efficiency relies in its ability to intercalate into DNA and inhibit the action of the topoisomerase II, an essential enzyme for the cell division and development.<sup>31</sup> This inhibition leads to the cell death by damaging the DNA. However, as almost all anti-cancer drugs, DOX causes harmful side effects.<sup>31</sup> It is then obvious that reducing its amount during the treatment is crucial in cancer therapy. The NPs developed in this work were designed to encapsulate DOX within the copolymer chains by supramolecular interactions and release it in high concentration once the targeted site and the desired temperature are reached. This should prevent any interaction between the drug and the healthy tissues during the DOX circulation within the body. DOX is well known to display hydrophobic properties, which could promote the association of the drug with the apolar domains of




Fig. 5 Magnetization curves of the  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{80}\text{-co-OEGMA}_{20})\text{-FA}$  (black),  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{65}\text{-co-OEGMA}_{35})\text{-FA}$  (red) and  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})\text{-FA}$  (blue) magnetic NPs.






Fig. 6 Temperature variation of ZFC and FC of  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-co-OEGMA}_{40})$ ,  $B = 750$  Oe.




Fig. 7 Cumulative DOX release by the core/shell NPs.

the grafted polymer chains. Hydrogen bonds and van der Waals interactions can also be considered but the main interactions that allow the drug penetration within the polymer shell are the apolar interactions.<sup>32,33</sup> Supramolecular interactions were used to encapsulate the drug for two main reasons, first to evaluate the stability of the encapsulation by those weak associations, second to develop a system that can release quickly with temperature without the need of a further step of drug linkage as it is the case when the drug is covalently grafted at the NPs surface. Indeed, while the copolymer chains are swollen below the LCST thanks to the hydrogen bonding with water, DOX can diffuse within the copolymer shell and be blocked by the apolar interactions with the polymer backbone. Once the LCST reached, the coil-to-globule transition resulting from the dehydration of the polymer chains and their collapse at the surface of the NPs will allow the release of DOX. A previous study demonstrated that these copolymer chains exhibit a sharp transition with the temperature leading to the fast release of the encapsulated drug.<sup>34</sup> We have chosen to perform experiments within a short time lapse (30 s) to demonstrate the temperature effect on our core/shell NPs.

Fig. 7 presents the evolution of the cumulative drug release *vs.* temperature for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{65}\text{-OEGMA}_{35})\text{-FA}$  and  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-OEGMA}_{40})\text{-FA}$  NPs. These samples were selected as they display an LCST in PBS close to 40 °C (based on the DLS results presented in Fig. 4), which is important for further applications as drug carrier. Surprisingly, almost no drug was released for both samples below the LCST (Fig. 7). DOX is indeed only stored in the carrier by supramolecular interactions that can be weakened in media with high ionic strength. By increasing the temperature, we could observe a change in the slope of the curve as soon as the LCST is reached. The release was expected to occur at 38 and 44 °C for  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-OEGMA}_{40})\text{-FA}$  and  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{65}\text{-OEGMA}_{35})\text{-FA}$  NPs, respectively, as shown by the LCST measurements. However, once DOX associated with the NPs, the starting temperature at which DOX is released, which is also the temperature at which the copolymer chain is supposed to

start to collapse, is shifted by 5 °C for both samples. DOX incorporated within the polymer shell seems to act as a kosmotrope molecule which is able to induce an early collapsing of copolymer chains.<sup>14,35,36</sup> Moreover, as seen in Fig. 7, the temperature range of the DOX release is larger (about 5 °C) for both samples compared to media without DOX, which is the indication that the NPs gradually release DOX. Interestingly, the evolution of the drug release rate is also influenced by the OEGMA amount within the polymer backbone.

For core/shell NPs containing a high amount of OEGMA, *i.e.*  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{60}\text{-OEGMA}_{40})\text{-FA}$  NPs, the temperature range between the starting of the drug release and its complete release is increased compared to  $\text{Fe}_3\text{O}_4@P(\text{MEO}_2\text{MA}_{65}\text{-OEGMA}_{35})\text{-FA}$  NPs. Nevertheless, only 50% of the total amount of the DOX was released within this very short time lapse (30 s), thus confirming the high diffusion of DOX within the copolymer shell<sup>34</sup> and indicating that longer times are necessary to release the total amount of the drug from the NPs.

Despite of the short time lapse, we showed that the loading of DOX within these NPs generate a more gradual collapse of the polymer chains. Such a phenomenon is accentuated when the macromolecules are more sterically hindered. Nevertheless, the controlled release of DOX from polymer-coated SPIONPs was obtained. For a good control of the drug release properties of those systems, the kosmotrope nature of DOX has to be taken into consideration when those systems will be considered as carrier for this anti-cancer molecule.

## 4. Conclusions

In this study, core/shell magnetic NPs covered by polymers allowing cancer targeting and macrophage evasion were successfully prepared.  $\text{Fe}_3\text{O}_4$  NPs have excellent dispersibility and stability in aqueous medium due to the surface coating by  $\text{MEO}_2\text{MA}$  and OEGMA. The LCST of the copolymer could be easily tuned by varying the initial monomer molar ratio. The combination of temperature-triggering release properties and





the possibility of FA targeting would allow to control where and when the drug will be released but longer time than 30 s have to be considered to release the total amount of the drug. We are currently investigating the drug release mechanism to further improve our systems for fast and efficient drug release properties. Thus, by virtue of these advantages,  $\text{Fe}_3\text{O}_4@\text{P}(\text{MEO}_2\text{MA}_x\text{-co-OEGMA}_y)\text{-FA}$  NPs can potentially be a good candidate for enhancing the targeting efficiency of cancer cells in bioimaging, biodetection, and other *in vivo* medical applications.

## Acknowledgements

The financial support was given by the Centre National de Recherche Scientifique (CNRS). The authors are thankful to Jaafar Ghanbaja for the TEM characterizations.

## References

- 1 D. Thassu, M. Deleers and Y. V. Pathak, *Nanoparticulate Drug Delivery Systems*, CRC Press, 2007.
- 2 H. M. Duvernoy, *The Human Brain: Surface, Three-Dimensional Sectional Anatomy with MRI, and Blood Supply*, Springer Science & Business Media, 2012.
- 3 L. Li, W. Jiang, K. Luo, H. Song, F. Lan, Y. Wu and Z. Gu, *Theranostics*, 2013, **3**, 595–615.
- 4 P. B. Santhosh and N. P. Ulrih, *Cancer Lett.*, 2013, **336**, 8–17.
- 5 R. Ghosh Chaudhuri and S. Paria, *Chem. Rev.*, 2012, **112**, 2373–2433.
- 6 N. Lee, D. Yoo, D. Ling, M. H. Cho, T. Hyeon and J. Cheon, *Chem. Rev.*, 2015, **115**, 10637–10689.
- 7 S. Laurent, D. Forge, M. Port, A. Roch, C. Robic, L. Vander Elst and R. N. Muller, *Chem. Rev.*, 2008, **108**, 2064–2110.
- 8 P. Kucheryavy, J. He, V. T. John, P. Maharjan, L. Spinu, G. Z. Goloverda and V. L. Kolesnichenko, *Langmuir*, 2013, **29**, 710–716.
- 9 M. Mahmoudi, H. Hofmann, B. Rothen-Rutishauser and A. Petri-Fink, *Chem. Rev.*, 2012, **112**, 2323–2338.
- 10 A. K. Gupta and M. Gupta, *Biomaterials*, 2005, **26**, 3995–4021.
- 11 S. Ganta, H. Devalapally, A. Shahiwala and M. Amiji, *J. Controlled Release*, 2008, **126**, 187–204.
- 12 M. A. C. Stuart, W. T. S. Huck, J. Genzer, M. Müller, C. Ober, M. Stamm, G. B. Sukhorukov, I. Szleifer, V. V. Tsukruk, M. Urban, F. Winnik, S. Zauscher, I. Luzinov and S. Minko, *Nat. Mater.*, 2010, **9**, 101–113.
- 13 I. Y. Galaev and B. Mattiasson, *Trends Biotechnol.*, 1999, **17**, 335–340.
- 14 D. Schmaljohann, *Adv. Drug Delivery Rev.*, 2006, **58**, 1655–1670.
- 15 E. Wischerhoff, K. Uhlig, A. Lankenau, H. G. Börner, A. Laschewsky, C. Duschl and J.-F. Lutz, *Angew. Chem., Int. Ed.*, 2008, **47**, 5666–5668.
- 16 M. Chanana, S. Jahn, R. Georgieva, J.-F. Lutz, H. Bäuml and D. Wang, *Chem. Mater.*, 2009, **21**, 1906–1914.
- 17 A. M. Jonas, K. Glinel, R. Oren, B. Nysten and W. T. S. Huck, *Macromolecules*, 2007, **40**, 4403–4405.
- 18 R. Barbey, L. Lavanant, D. Paripovic, N. Schüwer, C. Sugnaux, S. Tugulu and H.-A. Klok, *Chem. Rev.*, 2009, **109**, 5437–5527.
- 19 S. Edmondson, V. L. Osborne and W. T. S. Huck, *Chem. Soc. Rev.*, 2004, **33**, 14–22.
- 20 E. J. A. Dine, Z. Ferjaoui, T. Roques-Carmes, A. Schjen, A. Meftah, T. Hamieh, J. Toufaily, R. Schneider, E. Gaffet and H. Alem, *Nanotechnology*, 2017, **28**, 125601.
- 21 K. Matyjaszewski, W. Jakubowski, K. Min, W. Tang, J. Huang, W. A. Braunecker and N. V. Tsarevsky, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 15309–15314.
- 22 K. Matyjaszewski, H. Dong, W. Jakubowski, J. Pietrasik and A. Kusumo, *Langmuir*, 2007, **23**, 4528–4531.
- 23 H. Alem, A. Schejn, T. Roques-Carmes, J. Ghanbaja and R. Schneider, *Nanotechnology*, 2015, **26**, 335605.
- 24 V. M. Gaspar, E. C. Costa, J. A. Queiroz, C. Pichon, F. Sousa and I. J. Correia, *Pharm. Res.*, 2015, **32**, 562–577.
- 25 N. Li, T. Li, C. Liu, S. Ye, J. Liang and H. Han, *J. Biomed. Nanotechnol.*, 2016, **12**, 878–893.
- 26 B. Sahoo, K. S. P. Devi, R. Banerjee, T. K. Maiti, P. Pramanik and D. Dhara, *ACS Appl. Mater. Interfaces*, 2013, **5**, 3884–3893.
- 27 H. Maeda, K. Tsukigawa and J. Fang, *Microcirculation*, 2016, **23**, 173–182.
- 28 H. Maeda, *Adv. Drug Delivery Rev.*, 2015, **91**, 3–6.
- 29 Y.-X. J. Wang, S. M. Hussain and G. P. Krestin, *Eur. Radiol.*, 2001, **11**, 2319–2331.
- 30 A. Gloria, T. Russo, U. D'Amora, S. Zeppetelli, T. D'Alessandro, M. Sandri, M. Bañobre-López, Y. Piñeiro-Redondo, M. Uhlarz, A. Tampieri, J. Rivas, T. Herrmannsdörfer, V. A. Dediu, L. Ambrosio and R. D. Santis, *J. R. Soc., Interface*, 2013, **10**, 20120833.
- 31 K. Hagane, T. Akera and J. R. Berlin, *J. Pharmacol. Exp. Ther.*, 1988, **246**, 655–661.
- 32 A. Hervault, A. E. Dunn, M. Lim, C. Boyer, D. Mott, S. Maenosono and N. T. K. Thanh, *Nanoscale*, 2016, **8**, 12152–12161.
- 33 D. Missirlis, R. Kawamura, N. Tirelli and J. A. Hubbell, *Eur. J. Pharm. Sci.*, 2006, **29**, 120–129.
- 34 S. Louguet, B. Rousseau, R. Epherre, N. Guidolin, G. Goglio, S. Mornet, E. Duguet, S. Lecommandoux and C. Schatz, *Polym. Chem.*, 2012, **3**, 1408–1417.
- 35 S. Z. Moghaddam and E. Thormann, *RSC Adv.*, 2016, **6**, 27969–27973.
- 36 J. Iwahara, A. Esadze and L. Zandarashvili, *Biomolecules*, 2015, **5**, 2435–2463.

